Iron and acute kidney injury: potential biomarkers for diagnosis and therapy
Journal of Pharmacy and Pharmacology · 2026
DOI: 10.1093/jpp/rgag119 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmacy and Pharmacology, 2026. Verfasst von Zhidan Shi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China. Hauptthemen laut MEDLINE: Acute Kidney Injury, Iron. Die Arbeit nennt 254 Literaturangaben. Gefördert von: Scientific Research Project Program of Traditional Chinese Medicine in Hebei Province.
Abstract (Originalsprache)
Objectives
Acute kidney injury (AKI) is characterized by a rapid decline in renal excretory function and is associated with increased mortality and an elevated risk of developing or progressing to chronic kidney disease (CKD), posing a significant global public health challenge. Conventional assessment relies heavily on serum creatinine (SCr) and blood urea nitrogen (BUN), which have limitations in detecting early kidney injury. This review aims to elucidate the roles of iron metabolism and ferroptosis in AKI and evaluate the potential of iron-related proteins as biomarkers and therapeutic targets.
Methods
This review summarizes the molecular mechanisms regulating iron acquisition, storage, and efflux, examines the involvement of iron dysregulation and ferroptosis in AKI pathophysiology, and discusses the potential applications of iron-related proteins in AKI diagnosis, prognostic assessment, and therapeutic intervention. Key findings Ferroptosis, a form of regulated cell death characterized by iron-dependent lipid peroxidation, is closely implicated in the onset and progression of AKI. Dysregulated iron homeostasis contributes to oxidative stress, mitochondrial dysfunction, inflammatory responses, and renal cellular injury. Emerging evidence suggests that iron-related proteins may serve as promising biomarkers for early AKI detection and prognostic monitoring, while also providing potential molecular targets for therapeutic intervention.
Conclusions
Iron metabolism dysregulation and ferroptosis play important roles in AKI pathophysiology. Iron-related proteins represent promising candidates for improving early diagnosis, prognostic evaluation, and targeted treatment of AKI. Further investigation and clinical validation are needed to establish their diagnostic and therapeutic utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
- Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
- Institute of Chinese Medicinal Sciences, Guangdong Pharmaceutical University, Guangzhou 510006, China.
- Department of Traditional Chinese Medicine, CangZhou Medical College, CangZhou 061001, China.
- Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
ORCID-Profile: Zhidan Shi, Chu Zhang, Guangzhe Yao, Yiqi Yan, Ling He
Förderung
- Scientific Research Project Program of Traditional Chinese Medicine in Hebei Province
Zitieren
APA
Shi, Z., Zhang, C., Yan, C., Tian, M., Zeng, X., Xie, T., Zhao, D., Zhou, X., Wu, Q., Zhang, S., Yang, L., Chen, S., Yao, G., Yan, Y., & He, L. (2026). Iron and acute kidney injury: potential biomarkers for diagnosis and therapy. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgag119
Vancouver
Shi Z, Zhang C, Yan C, Tian M, Zeng X, Xie T, et al. Iron and acute kidney injury: potential biomarkers for diagnosis and therapy. Journal of Pharmacy and Pharmacology. 2026. doi:10.1093/jpp/rgag119
BibTeX
@article{Shi2026,
author = {Shi, Zhidan and Zhang, Chu and Yan, Chuang and Tian, Meng and Zeng, Xiaoqian and Xie, Tian and Zhao, Daxin and Zhou, Xinpeng and Wu, Qiwen and Zhang, Shusen and Yang, Linlin and Chen, Shuting and Yao, Guangzhe and Yan, Yiqi and He, Ling},
title = {Iron and acute kidney injury: potential biomarkers for diagnosis and therapy},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
doi = {10.1093/jpp/rgag119}
}
EUVIMED